SODAPHOS INJECTION FOR CATTLE

País: Austràlia

Idioma: anglès

Font: APVMA (Australian Pesticides and Veterinary Medicines Authority)

ingredients actius:

sodium phosphate(mono)(500mg/mL)

Disponible des:

PARNELL

Designació comuna internacional (DCI):

sodium phosphate(mono)(500mg/mL)

formulario farmacéutico:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

Unidades en paquete:

100mL

clase:

Veterinary Medicine

Fabricat per:

BAYER AUSTRALIA

Grupo terapéutico:

CATTLE | BEEF | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | COW | DAIRY COW | HEIFER | STEER

Área terapéutica:

phosphorus supplement

indicaciones terapéuticas:

PHOSPHORUS DEFICIENCY

Resumen del producto:

An aid in the treatment of phosphorus deficiency in cattle.

Estat d'Autorització:

Registered but not available

Data d'autorització:

1995-07-03

Informació per a l'usuari

SODAPHOS INJECTION FOR CATTLE
DRAFT LABEL 100ML
SEPTEMBER 23, 1997
PAGE 1 OF 1
______________________________________________________________________________________________________________________________
INFOPEST VERIFIES THAT THIS LABEL IS CONSISTENT WITH THE
NRA APPROVED TEXT LABEL OF 6/10/98_
FOR ANIMAL TREATMENT ONLY
SODAPHOS
INJECTION FOR CATTLE
ACTIVE CONSTITUENT:
SODIUM ACID PHOSPHATE 500mg/mL
AN AID IN THE TREATMENT OF PHOSPHORUS DEFICIENCY
IN CATTLE
100ML
PARNELL LABORATORIES (AUST) PTY. LTD.
6/476 Gardeners Road, Alexandria, N.S.W. 2015
DIRECTIONS FOR USE:
ADULT CATTLE: PRIMARY PHOSPHORUS DEFICIENCY:
20-40g/ animal (10-20mL/100kg bodyweight) daily for 1 to 3 days by
subcutaneous
injection.
PHOSPHORUS DEFICIENCY ASSOCIATED WITH PARTURIENT PARESIS:
30g (60mL) diluted in
240mL Water For Injections BP by intravenous injection; specific
therapy of the
primary disease should be implemented concurrently.
WITHHOLDING PERIOD NIL
CAUTION: AVOID CARCASE DAMAGE
1.Sterilise
all
injection
apparatus
by
boiling
before
use.
Avoid
use
of
strong
disinfectants on apparatus.
2.Maintain cleanliness at all times.
3.Keep needles sharp and clean. Replace frequently.
4.Use shortest needle possible, certainly not exceeding 15mm.
5.This product must be injected only under the skin.
PRECAUTIONS:
In areas of established phosphorus deficiency oral phosphorus
supplementation
should be provided.
Dispose of empty container or expired product by wrapping with paper
and putting in
garbage.
Store below 30
o
C (Room Temperature).
NRA 37719/01
B Exp.

Fitxa tècnica

DATE OF ISSUE: DECEMBER 2008
M
M
A
A
T
T
E
E
R
R
I
I
A
A
L
L
S
S
A
A
F
F
E
E
T
T
Y
Y
D
D
A
A
T
T
A
A
S
S
H
H
E
E
E
E
T
T
:
:
S
S
O
O
D
D
A
A
P
P
H
H
O
O
S
S
1
STATEMENT OF HAZARDOUS NATURE:
Non-hazardous substance according to criteria of Worksafe Australia.
MANUFACTURER COMPANY DETAILS:
Bomac Pty Ltd
ADDRESS
15/36 Leighton Place
Hornsby NSW 2077
Australia
TELEPHONE NUMBER
61 (0)2 9987 4922
EMERGENCY TELEPHONE NUMBER
61 (0)2 9987 4922 (Business Hours)
FACSIMILE NUMBER
61 (0)2 9987 4188
IDENTIFICATION
PRODUCT NAME
Sodaphos Injection for Cattle
OTHER NAMES
Sodaphos, Phosphate injection
U.N. NUMBER
No UN number allocated
DANGEROUS GOODS CLASS AND SUBSIDIARY RISK
No class and subsidiary risk allocated
HAZCHEM CODE
No Hazchem code allocated
POISONS SCHEDULE
Not scheduled
PACKAGING
100mL amber glass vial with rubber plug and aluminium cap, labelled.
USE
FOR ANIMAL TREATMENT ONLY.
For the treatment of phosphorus deficiency in cattle.
PHYSICAL DESCRIPTION AND PROPERTIES:
DATE OF ISSUE: DECEMBER 2008
M
M
A
A
T
T
E
E
R
R
I
I
A
A
L
L
S
S
A
A
F
F
E
E
T
T
Y
Y
D
D
A
A
T
T
A
A
S
S
H
H
E
E
E
E
T
T
:
:
S
S
O
O
D
D
A
A
P
P
H
H
O
O
S
S
2
APPEARANCE AND ODOUR
SOLUBILITY IN WATER
Clear colourless solution
Aqueous solution
BOILING POINT
MELTING POINT
Not determined
Not determined
VAPOUR PRESSURE
SPECIFIC GRAVITY
Not determined
Not determined
FLASH POINT
FLAMMABILITY LIMITS
Not determined
Not determined
OTHER PROPERTIES
Not applicable
INGREDIENTS:
CHEMICAL ENTITY
CAS NUMBER
PROPORTION
Sodium Acid Phosphate
7558-80-7
50%w/v
Water
7732-18-5
to 100%
HEALTH HAZARD INFORMATION
HEALTH EFFECTS:
ACUTE EXPOSURE:
Adverse effects of parenteral phosphorus administration may include
hypocalcaemic tetany, hypotension,
oedema and acute renal failure. Those effects are less likely
following oral administration.
SWALLOWED
May be absorbed via the gastrointestinal tract. Adverse effects of
oral administration may include nausea,
vomiting, diarrhoea and abdominal pain.
EYE
May cause irritation.
SKIN
No effects reported.
INHALED
No effects reported.
CHRONI